General Information
Version
2.1
Revision date
2025-02-28
Product name
Cyltezo (adalimumab-adbm), Solution for injection
Product Synonyms
Cyltezo® Solution for injection, Adalimumab-adbm solution for injection, Cyltezo® PFS, Solution for injection, Adalimumab- adbm PFS, solution for injection; Cyltezo 40 mg/0,4 mL (100 mg/0,4 mL), Cyltezo 40 mg/0,8 mL (50 mg/0,8 mL), Cyltezo 20 mg/0,4 mL (50 mg/0,4 mL), Cyltezo 10 mg/0,2 mL (50 mg/0,2 mL) with active ingredient: Adalimumab-adbm (antibody)
1.2.1 Relevant identified uses
Pharmaceutical
1.2.2. Uses advised against
Safety Data Sheet only for the professional user
supplier name
Boehringer Ingelheim Pharmaceuticals Inc
Emergency telephone
+1 703-527-3887, +1 703-741-5970
Icons in SDS
Company Information
company name
Boehringer Ingelheim Pharmaceuticals Inc
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
Section 2
SECTION 2: Hazards identification
2.2 Label elements
No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) re- quired.
2.3 Other hazards
This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet).
2.1 Classification of the substance or mixture
1910.1200) Not meeting criteria for classification as hazardous, due to data availability or due to lack of data.
